MacroGenics Stock Price, Forecast & Analysis (NASDAQ:MGNX)

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

MacroGenics Inc (NASDAQ:MGNX) issued its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.94) by $0.03. The biopharmaceutical company had revenue of $18.74 million for the quarter, compared to analysts' expectations of $23.33 million. MacroGenics had a negative net margin of 303.08% and a negative return on equity of 59.67%. View MacroGenics' Earnings History.

MacroGenics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for MacroGenics.

12 analysts have issued 12-month target prices for MacroGenics' stock. Their forecasts range from $14.00 to $50.00. On average, they expect MacroGenics' share price to reach $25.38 in the next twelve months. This suggests a possible upside of 194.1% from the stock's current price. View Analyst Price Targets for MacroGenics.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MacroGenics.

Press coverage about MGNX stock has been trending somewhat negative on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. MacroGenics earned a daily sentiment score of -1.6 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for MacroGenics.

MacroGenics saw a decrease in short interest in October. As of October 31st, there was short interest totalling 3,630,000 shares, a decrease of 16.9% from the September 30th total of 4,370,000 shares. Based on an average daily trading volume, of 467,700 shares, the short-interest ratio is currently 7.8 days. Approximately 8.3% of the company's stock are short sold. View MacroGenics' Current Options Chain.

Some companies that are related to MacroGenics include Aimmune Therapeutics (AIMT), Tricida (TCDA), Alder Biopharmaceuticals (ALDR), Madrigal Pharmaceuticals (MDGL), Gossamer Bio (GOSS), Zymeworks (ZYME), Epizyme (EPZM), Nabriva Therapeutics (NBRV), Dicerna Pharmaceuticals (DRNA), Constellation Pharmaceuticals (CNST), Innoviva (INVA), Enanta Pharmaceuticals (ENTA), BELLUS Health (BLUSF), Supernus Pharmaceuticals (SUPN) and Y-mAbs Therapeutics (YMAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), NVIDIA (NVDA), Celgene (CELG), Sangamo Therapeutics (SGMO), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), InterDigital Wireless (IDCC) and Karyopharm Therapeutics (KPTI).

MacroGenics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (1.64%), Massachusetts Financial Services Co. MA (0.29%), Alps Advisors Inc. (0.20%), California Public Employees Retirement System (0.19%), Rhumbline Advisers (0.14%) and Campbell & CO Investment Adviser LLC (0.06%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jeffrey Stuart Peters, Jon Marc Wigginton, Lynn Cilinski, Matthew K Fust and Thomas Spitznagel. View Institutional Ownership Trends for MacroGenics.

MGNX stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Alps Advisors Inc.. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, Jeffrey Stuart Peters, Matthew K Fust and Thomas Spitznagel. View Insider Buying and Selling for MacroGenics.

MGNX stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Massachusetts Financial Services Co. MA, Campbell & CO Investment Adviser LLC, Tower Research Capital LLC TRC and Rhumbline Advisers. View Insider Buying and Selling for MacroGenics.

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MGNX stock can currently be purchased for approximately $8.63.

MacroGenics has a market capitalization of $422.15 million and generates $60.12 million in revenue each year. The biopharmaceutical company earns $-171,450,000.00 in net income (profit) each year or ($4.19) on an earnings per share basis. MacroGenics employs 364 workers across the globe.View Additional Information About MacroGenics.

The official website for MacroGenics is http://www.macrogenics.com/.

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.